The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Abstract
This study demonstrates that type I IFNs are an early and critical regulator of NK cell numbers, activation, and antitumor activity. Using both IFNAR1- and IFNAR2-deficient mice, as well as an IFNAR1-blocking Ab, we demonstrate that endogenous type I IFN is critical for controlling NK cell-mediated antitumor responses in many experimental tumor models, including protection from methylcholanthrene-induced sarcomas, resistance to the NK cell-sensitive RMA-S tumor and cytokine immunotherapy of lung metastases. Protection from RMA-S afforded by endogenous type I IFN is more potent than that of other effector molecules such as IFN-γ, IL-12, IL-18, and perforin. Furthermore, cytokine immunotherapy using IL-12, IL-18, or IL-21 was effective in the absence of endogenous type I IFN, however the antimetastatic activity of IL-2 was abrogated in IFNAR-deficient mice, primarily due to a defect in IL-2-induced cytotoxic activity. This study demonstrates that endogenous type I IFN is a central mediator of NK cell antitumor responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Self-citationLe Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 974
Cytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703
The human interferon $alpha;/$beta; receptor: Characterization and molecular cloning
NOVICK, D. (1994) · Cell · doi:10.1016/0092-8674(94)90154-6 · Cited by 667
Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., & Mescher, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4465 · Cited by 630
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
Luft, T., Pang, K. C., Thomas, E., Hertzog, P., Hart, D. N. J., Trapani, J., & Cebon, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1947 · Cited by 611
Self-citationNguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Self-citationUzé, G., Lutfalla, G., & Gresser, I. (1990) · Cell · doi:10.1016/0092-8674(90)90738-z · Cited by 574
Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity
HERBERMAN, R. R., ORTALDO, J. R., & BONNARD, G. D. (1979) · Nature · doi:10.1038/277221a0 · Cited by 522
Type I Interferon Sensitizes Lymphocytes to Apoptosis and Reduces Resistance to Listeria Infection
Carrero, J. A., Calderon, B., & Unanue, E. R. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040769 · Cited by 390
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379
Self-citationHwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., & Kola, I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11284 · Cited by 377
Self-citationNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Self-citationRequirement for IRF-1 in the microenvironment supporting development of natural killer cells
Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T. A., Taniguchi, T., & Taki, S. (1998) · Nature · doi:10.1038/35636 · Cited by 354
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342
Self-citationIL-21 Induces the Functional Maturation of Murine NK Cells
Brady, J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2048 · Cited by 303
Self-citationThe Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
Smyth, M. J., Taniguchi, M., & Street, S. E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2665 · Cited by 301
Self-citationPerforin Is a Major Contributor to NK Cell Control of Tumor Metastasis
Smyth, M. J., Thia, K. Y. T., Cretney, E., Kelly, J. M., Snook, M. B., Forbes, C. A., & Scalzo, A. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6658 · Cited by 295
Self-citationFenner, J. E., Starr, R., Cornish, A. L., Zhang, J.-G., Metcalf, D., Schreiber, R. D., Sheehan, K., Hilton, D. J., Alexander, W. S., & Hertzog, P. J. (2006) · Nature Immunology · doi:10.1038/ni1287 · Cited by 293
Self-citationInnate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
Self-citationSheehan, K. C. F., Lai, K. S., Dunn, G. P., Bruce, A. T., Diamond, M. S., Heutel, J. D., Dungo-Arthur, C., Carrero, J. A., White, J. M., Hertzog, P. J., et al. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.804 · Cited by 260
Self-citationDistinct Requirements for IFNs and STAT1 in NK Cell Function
Lee, C.-K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B., & Levy, D. E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3571 · Cited by 217
Cancer immunotherapy: The interferon-α experience
Kirkwood, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33078 · Cited by 213
Interferon‐β mediates stromal cell rescue of T cells from apoptosis
Pilling, D., Akbar, A. N., Girdlestone, J., Orteu, C. H., Borthwick, N., Amft, N., Scheel‐Toellner, D., Buckley, C. D., & Salmon, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-# · Cited by 195
Studies of interferon as a regulator of hematopoietic cell proliferation.
Raefsky, E. L., Platanias, L. C., Zoumbos, N. C., & Young, N. S. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2507 · Cited by 186
Hayakawa, Y., Kelly, J. M., Westwood, J. A., Darcy, P. K., Diefenbach, A., Raulet, D., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5377 · Cited by 185
Self-citationPerforin dependence of natural killer cell‐mediated tumor control in vivo
van den Broek, M. F., Kägi, D., Zinkernagel, R. M., & Hengartner, H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251246 · Cited by 171
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
Smyth, M. J., Swann, J., Kelly, J. M., Cretney, E., Yokoyama, W. M., Diefenbach, A., Sayers, T. J., & Hayakawa, Y. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041522 · Cited by 169
Self-citationDuncan, G. S., Mittrücker, H.-W., Kägi, D., Matsuyama, T., & Mak, T. W. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.5.2043 · Cited by 135
Interferon Induces Natural Killer Cell Blastogenesis In Vivo
Biron, C. A., Sonnenfeld, G., & Welsh, R. M. (1984) · Journal of Leukocyte Biology · doi:10.1002/jlb.35.1.31 · Cited by 118
Type I Interferon-Associated Recruitment of Cytotoxic Lymphocytes
Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T. R. M., & Tüting, T. (2005) · American Journal of Clinical Pathology · doi:10.1309/4ej9-kl7c-gden-vvle · Cited by 99
Altered natural killer cell repertoire in Tap-1 mutant mice.
Ljunggren, H., Kaer, L. V., Ploegh, H. L., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6520 · Cited by 97
Generation and characterization of monoclonal antibodies specific for the human IFN-gamma receptor.
Sheehan, K. C. F., Calderón, J., & Schreiber, R. D. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4231 · Cited by 76
Self-citationDeonarain, R., Verma, A., Porter, A. C. G., Gewert, D. R., Platanias, L. C., & Fish, E. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2230460100 · Cited by 76
IFN-α Subtypes Differentially Affect Human T Cell Motility1
Foster, G., Masri, S. H., David, R., Jones, M., Datta, A., Lombardi, G., Runkell, L., de Dios, C., Sizing, I., James, M., et al. (2004) · Journal of Immunology · doi:10.4049/jimmunol.173.3.1663 · Cited by 52
Gresser, I., Maury, C., Woodrow, D. F., Moss, J., Grütter, M. G., Vicnaux, F., Belardelli, F., & Maunoury, M. T. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410124 · Cited by 46
Badr, G., Borhis, G., Treton, D., & Richard, Y. (2005) · International Immunology · doi:10.1093/intimm/dxh227 · Cited by 39
Gresser, I., Maury, C., Vignaux, F., Haller, O., Belardelli, F., & Tovey, M. G. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.4.1271 · Cited by 35
Cited by
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Self-citationType I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citationInterferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Self-citationHarnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Metadata
- Authors
- Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06
- Volume
- 178
- Issue
- 12
- Pages
- 7540-7549
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1531206210
- Cited by
- 339
- References
- 43
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.